Upside – $LQDA +41.0% ($380.7M global settlement resolves six lawsuits and preserves uninterrupted YUTREPIA commercialization) – $TCRT +25.5% (completed Velaris acquisition and secured an approximately $350M private placement to fund development through 2029) – $VSTM +11.0% (VS-7375 produced a 50% confirmed response rate in eight second-line pancreatic-cancer patients, with FDA alignment on a Phase 3 …
Read in context ›Verastem Stock (VSTM)
Track Verastem stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
VSTM
Verastem
healthcare
At close
$6.87
â–¼ -0.54 (-7.29%)
Nov 18, 4:00 PM ET
After-hours
$6.90
â–² +0.03 (+0.44%)
Nov 18, 6:33 PM ET
Market Cap
$933.77M
P/E Ratio
—
1Y Return
-19.02%
EPS (TTM)
-$1.85
Read the latest TheStreet Pro articles mentioning Verastem, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
1 articleDaily Diary Mentions
1 mentionSelect Premarket Movers